TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study to Asses Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AZD0328 in Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of schizophrenia according to the DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition)~* Low level of Extra-pyramidal symptoms~* No clinically significant findings on physical examination~Exclusion Criteria:~* Diagnosis of schizoaffective or schizophreniform disorders~* Any significant psychiatric or neurological disease other than schizophrenia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): AZD0328 low dose
- 2 (Type: EXPERIMENTAL): AZD0328 Optimal dose
- 3 (Type: EXPERIMENTAL): AZD0328 High dose
- 4 (Type: PLACEBO_COMPARATOR): Placebo Comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological diagnosis of NPC~* Age \> 18 years old~* Measurable metastatic or recurrent disease (s)~* Received one prior chemotherapy regimen for metastatic or recurrent NPC which relapsed or became refractory before entry.~* ECOG PS 0, 1 or 2~* WBC \> 3,500/uL and ANC \> 1,500/uL Platelet \> 100,000/uL Creatinine - within normal limits SGOT \< 3 X UNL Bilirubin \< 2.0 mg/dL~* Ejection fraction \> 45% and no history of myocardial infarction or congestive heart failure in the last 6 months. No history of cardiac ventricular arrythmia or ventricle tachycardia, or uncontrolled atrial fibrillation or supraventricular tachycardia with hemodynamic compromising status.~* Random blood glucose level \< 250 mg~* Signed informed consent~Exclusion Criteria:~* Received more than one prior chemotherapy for metastatic or recurrent disease~* Ejection fraction \< 45%~* WBC \< 3,500/UL or ANC \< 1,500/UL or P/t \< 100,000/UL or SCOT\> 3 x UNL or Bilirubin \> 2.0 mg/dL or Creatinine \> UNL~* ECOG PS \> 3~* Hx of myocardial infarction within last 6 months~* Random blood glucose level less than or equal 250 mg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ifosfamide and Doxorubicin (Type: EXPERIMENTAL): Single arm treatment with Ifosfamide and Doxorubicinin patients with Refractory Nasopharyngeal Carcinoma

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study to Assess the Value of EUS vs EGD in Emergency Room Patients Referred for EGD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* EGD requested by the consulting gastroenterologist~* Informed consent~Exclusion Criteria~* Evidence of hemodynamic instability and/or ongoing active GI bleeding.~* Any suspicion of obstruction distal to the angle of Treitz.~* EGD or EUS cannot be performed before 12PM.~* Previous barium study, EGD, US, abdomino-pelvic CT, or abdomino-pelvic MRI within the last 6 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ESOPHAGO-GASTRO-DUODENOSCOPY (EGD) (Type: ACTIVE_COMPARATOR): GI consult Procedure performed is EGD
- ENDOSCOPIC ULTRASOUND (EUS) (Type: EXPERIMENTAL): GI consult Procedure performed is EUS

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: REassessement After Hospitalization for Sars-COV-2 disordER

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patient who was hospitalized within 3 to 6 months for a sars-CoV infection~Exclusion Criteria:~* Absence of signed informed consent~* pregnancy or breastfeeding~* patient under guardianship or curatorship

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Iloprost for the Treatment of Pulmonary Hypertension in Adults With Congenital Heart Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than or equal to 18 years old~* Congenital heart disease with pulmonary arterial hypertension and cyanosis (resting oxygen saturation \< 90% on room air)~* Stable on oral therapy (PDE5 inhibitor and/or endothelin blockade) for at least three months~Exclusion Criteria:~* Age \< 18 years old~* Current intravenous or subcutaneous prostacyclin therapy~* Resting Systemic Hypotension (Systolic blood pressure \< 85 mmHg)~* Women who are pregnant or may become pregnant (unwilling to utilize effective contraception), as well as nursing mothers~* Inability to ambulate~* Planned surgical procedure during the study period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Iloprost (Type: EXPERIMENTAL): Participants will be administered iloprost at 5 mcg/dose x 6 doses daily for 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: CPT-3 in Normal Pressure Hydrocephalus

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients being referred for CSF tap test as part of routine clinical assessment of idiopathic Normal Pressure Hydrocephalus by their medical provider~* adults older than 18 years old~Exclusion Criteria:~* premorbid neurodegenerative disease (e.g. Alzheimer's Disease, Frontotemproal Dementia, Parkinson's Disease)~* serious acquired brain injury such as moderate to severe traumatic brain injury, large ischemic strokes~* seizure disorders~* serious neuropsychiatric disease (e.g. schizophrenia, bipolar disorder, major depressive disorder, active alcohol or drug abuse)~* untreated vitamin deficiencies (B12, Wernicke-Korsakoff Syndrome)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cannabis for Spasticity in Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of clinically definite multiple sclerosis as defined by Poser criteria~* Moderate or severe spasticity~* Age 21 or older~* Must live close to the Sacramento, CA area~Exclusion Criteria:~* Preexisting pulmonary conditions, including poorly controlled asthma, chronic bronchitis, emphysema, bronchiectasis, and other significant pulmonary disorders~* Preexisting cardiac conditions, including ischemic heart disease, congestive heart failure, and other significant cardiac disorders~* Inability to abstain from tobacco or marijuana smoking, or use of alcohol or sedative or hypnotic medications during the duration of the study~* Pre-existing dementia, mania, depression or schizophrenia or other poorly controlled psychiatric illness~* Past history of abuse of recreational drugs, including marijuana and alcohol in the last 12 months~* History of or currently meets DSM-IV criteria for dependence on cannabis~* Use of cannabis, marijuana, or THC in the last four weeks~* Preexisting dementia, mania, depression, or schizophrenia or other poorly controlled psychiatric illness~* Exacerbation of MS within 30 days prior to screening visit~* Current use of cyclophosphamide, mitoxantrone, or cladribine~* Arthritis, bony and soft tissue disorders interfering with spasticity measures~* Inability to provide informed consent~* Recent cannabis use of more than twice per week one month prior to study entry~* For females of child bearing potential, inability to comply with adequate contraception

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1) Inhaled Cannabis (Type: ACTIVE_COMPARATOR): Inhaled cannabis is compared to oral placebo.
- 2) Oral THC (Type: ACTIVE_COMPARATOR): Inhaled placebo is compared to oral THC.
- 3) Placebo (Type: PLACEBO_COMPARATOR): Inhaled placebo is compared to oral placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Optimisation of Antipsychotic Drug Use in Older People

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~Treatment and Control (antipsychotic free) Group~Schizophrenia~* meet diagnostic criteria for schizophrenia-like illness~* aged between 60 and 95 years of age~* score \<6 on the Geriatric depression scale~Alzheimer's~* meet diagnostic criteria for AD~* score \<=4 on the Modified Hachinski Ischaemia Scale~* score \< 8 on a modified version of the UPDRS~* aged between 60 and 95 years of age~* score \<6 on the Geriatric depression scale~Exclusion Criteria~Treatment Group~Schizophrenia~* current or past history of addiction, traumatic brain injury or epilepsy~* prescribed any drug that interferes with brain dopamine in past 2 weeks (6 weeks if depot antipsychotic medication).~* medical conditions that might affect Ability to tolerate a brain scan~* unable to give informed consent~Alzheimer's~* current or past history of psychiatric illness, traumatic brain injury or epilepsy~* prescribed an antipsychotic or other oral drug that interferes with brain dopamine function within the past 2 weeks (6 weeks if depot antipsychotic medication).~* medical conditions that might affect a person's ability to tolerate a brain scan~Control (antipsychotic free) Group~Schizophrenia~* Prescribed psychotropic medication~* unable to give informed consent~Alzheimer's~• Prescribed psychotropic medication

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Patients - dose titration (Type: EXPERIMENTAL): Amisulpride 50-200mg, 4-12 weeks, with brain imaging

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prevalence and Clinical Course of Chronic Hep B Infection in IBD and Rheumatologic Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All IBD and rheumatologic patients aged 18 years or older~Exclusion Criteria:~* Lack of consent~* Patients with evidence of other chronic liver disease,metabolic syndrome, men consuming more than 30 g of alcohol per day and women consuming more than 20 g of alcohol per day, patients with liver decompensation, HCC, previous liver surgery or liver transplantation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HBV DNA level monitoring (Type: OTHER): Group with HBV DNV level being monitored regularly

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Repetitive TMS and Occupational Therapy in Children and Young Adults With Chronic Hemiparesis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 10 years; \< 21 years~* Hemiparesis~* Manual Ability Classification System (MACS) level I through IV~* Provision of written informed consent by the patient and/or guardian, including understanding that insurance may be billed for the occupational therapy~* Written assent form signed by participants younger than 18 years of age~Exclusion Criteria:~* Underlying degenerative or metabolic disorder or supervening medical illness~* Severe depression or other psychiatric disorder~* Any participant who is pregnant~* Any contraindication to TMS (i.e., intracranial metal implants, shunts, ports, pacemaker, baclofen pumps)~* Any changes or addition of neuropsychiatric medications within 1 month of starting the study or during course of the study (if applicable)~* Any botulinum toxin (Botox, Myobloc) or phenol injection within the last 3 months prior to the study or during the course of the study (if applicable)~* Any upper extremity surgery within the last 6 months prior to the study or scheduled during the course of the study (if applicable)

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Active rTMS (Type: ACTIVE_COMPARATOR): Participants will receive daily active rTMS with occupational therapy immediately following rTMS for 10 consecutive weekdays.
- Sham rTMS (Type: SHAM_COMPARATOR): Participants will receive daily sham rTMS with occupational therapy immediately following rTMS for 10 consecutive weekdays.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Gastric pH Control With High Dose Intravenous or Oral Esomeprazole

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients admitted with diagnosis of upper gastrointestinal bleeding aged between 18 and 80~* Endoscopic confirmation of a bleeding duodenal or gastric ulcer to which endoscopic control has been obtained~* Absence of H. pylori infection~* Informed written consent~Exclusion Criteria:~* Known incompatibility to the study drugs;~* Known incompatibility and hypersensitivity to proton pump inhibitor~* H. pylori infection~* Recent H2RA or PPI use (within last 4 weeks)~* Concomitant use of medications that may interfere gastric acid secretion or motility (e.g. anticholinergic, metoclopramide, domperidone)~* Pregnancy or lactation;~* Non-compliance e.g. mental subordination~* Nasopharyngeal or oropharyngeal pathology that would prevent passage of a nasal catheter~* Significant liver disease as PPI is metabolized by the cytochrome P-450 system~* Previous gastric surgery~* Chronic Aspirin user~* Presence of esophageal/ gastric varices~* Moribund patients, terminal malignancy \& patients with severe renal disease~* Patient unable to give written consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- IV Nexium (Type: ACTIVE_COMPARATOR): Intravenous bolus injection of esomeprazole (Astra Pharmaceutica AG, Dietikon, Switzerland) 80mg followed by continuous intravenous infusion of 8mg per hour for 24 hours
- Oral Nexium (Type: ACTIVE_COMPARATOR): Oral esomeprazole (Astra Pharmaceutica AG, Dietikon, Switzerland) 40mg every 12 hours for 24 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Efficacy of Diuretics for Symptomatic Malignant Ascites Episodes in Advanced Stage of Cancer (DIASC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with advanced stage cancer~* First episode of malignant ascites~* Grade 2 or 3 ascites~* Clinically symptomatic ascites requiring paracentesis due to : abdominal pain or heaviness, dyspnoea, orthopnoea, nausea/vomiting, anorexia, early satiety, gastro-oesophageal reflux, lower limb and genital oedema~* Age ≥ 18 years~* Performance status ≤ 3~* Life expectancy ≥ 1 month~* Absence of contra-indication to diuretic treatment~* Patient regularly followed up by a palliative care or supportive care team~* Signed and dated informed consent~Exclusion Criteria:~* Hepatic disorders : cirrhosis, hepatitis, hepatocellular insufficiency, hepatic encephalopathy~* Non malignant ascites~* Hydroelectrolytic disorders: hyponatremia (\< 130 mmol/L) or hyperkaliemia (\> 5 mmol/L) or severe hypokaliemia (\< 3 mmol/L)~* Functional acute renal insufficiency~* Urinary disorders : Obstruction in the urinary tract, Oliguria/anuria~* Chronic renal failure~* Patient unable to swallow~* Sulfamides allergy~* Hypersensitivity to spironolactone or to any of the excipients~* Hypersensitivity to furosemide or to any of the excipients~* Pregnant or breastfeeding women~* Patient under guardianship

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A : observation (Type: NO_INTERVENTION): Clinical monitoring and best supportive care.
- B : diuretics (Type: ACTIVE_COMPARATOR): Diuretics (spironolactone +/- Furosemide) are administered the day after the paracentesis and until the next episode requiring paracentesis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Multikine in the Treatment of Perianal Warts

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥18 years of age~* Diagnosed with perianal condyloma by primary clinician~* HIV-infected, may be on or off of antiretroviral therapy~* any CD4 count will be considered appropriate for study~* Blood WBC \> 2.0x103/mm3 and absolute neutrophils count \> 500~* Blood hemoglobin \> 10.0 g/dL~* Blood platelet count \> 50x103/mm3~* Serum total bilirubin \< 6.0 mg/dL (participants taking atazanavir-based ARV regimens may have elevated total bilirubin but are generally \< 6)~* Blood aspartate aminotransferase (AST) \< 100 U/L (\<2 ULN)~* Blood alanine aminotransferase (ALT) \< 130 U/L (\<2 ULN)~* Serum creatinine \< 1.5 mg/dL~* ECOG performance status \< 3~* If a subject is of reproductive potential he/she and her/his sexual partner MUST be willing and able to utilize effective methods of contraception (e.g., birth control pill, barrier methods with spermicide - as applicable) for the duration of the study including the study follow-up period.~Exclusion Criteria:~* Anal cancer (current or history of)~* Inability to attend study visits~* Participation in any other drug study~* History of asthma~* History of organ transplantation or requiring chronic administration of immune suppressive drugs in the last 6 months~* For women, neither pregnant nor lactating~* In the opinion of the PI, the subject may not be able to tolerate the study treatment regimen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A (Type: EXPERIMENTAL): Cohort A participants will undergo perilesional Multikine injections (200IU) once daily, Monday through Friday, for 14 days, off for 14 days, then again once daily, Monday through Friday for 14 days.
- Cohort B (Type: EXPERIMENTAL): Cohort B participants will undergo perilesional Multikine injections 400IU once daily, Monday through Friday, for 14 days, off for 14 days, then again once daily, Monday through Friday for 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues